Drug Trial Radar · NCT07379047
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Aug 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Ningbo Newbay Technology Development Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NB003-04 is a phase II/III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or the legal adult age of consent per local regulations, whichever is older). Participants who are eligible for this study are those who have experienced disease progression or documented intolerance following treatment with either imatinib and sunitinib or following treatment with imatinib. This study consists of two parts. Part 1 (hereinafter referred to as Part 1) compares the efficacy of NB003 versus regorafenib in patients who need a third-line therapy for GIST who have failed sequential therapy with imatinib and sunitinib. Part 2 (hereinafter referred to as Part 2) evaluates the efficacy of NB003 in patients who need a second-line therapy for GIST who have failed treatment with imatinib.
Conditions
- GIST - Gastrointestinal Stromal Tumor
- Advanced
Interventions
NB003Drug
15 mg BID on a continuous schedule in 28-day cycles.
regorafenibDrug
Regorafenib is an approved multi-kinase inhibitor administered orally at a dose of 160 mg once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From randomization until database cut-off, approximately 28 months
- Objective response rate (ORR)Time frame: approximately 24 months since the first subject enrolled
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guandong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Guangxi Medical University Affiliated Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Cancer Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Xiangya Hospital, Central South University
Changsha, Hunan, China · Not yet recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Not yet recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Kangbuk Samsung Hospital
Seoul, South Korea · Not yet recruiting
Samsung Medical Center
Seoul, South Korea · Not yet recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.